UPCARE
LIVE

Serial Number

79298532

Owner

APEX BIOTECH RESEARCH PTY LTD

Attorney

Katherine P. Califa

Filing Date

Oct 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

UPCARE Trademark

Serial Number: 79298532 • Registration: 6648773

UPCARE is a trademark filed by APEX BIOTECH RESEARCH PTY LTD on October 21, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

APEX BIOTECH RESEARCH PTY LTD (3 trademarks)

PO Box 649

Entity Type: 99

Trademark Details

Filing Date

October 21, 2020

Registration Date

February 22, 2022

Published for Opposition

December 7, 2021

Goods & Services

Acne treatment preparations in the form of cleansers; anti-bacterial pharmaceutical preparations; Capsules sold empty for pharmaceutical purposes; effervescent analgesic pharmaceutical preparations; Extracts of plants in capsule form for pharmaceutical purposes; Throat lozenges for pharmaceutical purposes; pharmaceutical compound eye-drops; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations containing vitamins for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for animals for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for health care for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for human use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for nasal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for oral use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for personal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of acne; Pharmaceutical preparations for veterinary use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations in the form of emulsions for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations in the form of throat lozenges; Pharmaceutical preparations in the form of tablets for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical products for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical products derived from natural sources for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical products for use by humans for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical products in gel form for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical tablets for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; plant extracts for pharmaceutical use; Drug delivery agents in the form of tablets that facilitate the delivery of pharmaceutical preparations; medicated mouth spray; mouth sprays for medical use; medicated throat sprays; medicated mouthwashes; medical mouthwashes; mouthwashes and gargles for medical purposes; dietary supplements; dietary supplements for animals; herbal dietary supplements; vitamin supplements; vitamin supplements for animals; Nutritionally fortified herbal beverages for medicinal use; medical toothpastes; medicated toothpaste; eye drops; dietary supplements with a cosmetic effect

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 16, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 27, 2022 FICS
FINAL DISPOSITION PROCESSED
Jul 27, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 22, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 22, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 7, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 7, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Dec 6, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 17, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 17, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 17, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 1, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 5, 2021 TROA
REFUSAL PROCESSED BY IB
Apr 25, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 5, 2021 RFCS
REFUSAL PROCESSED BY MPU
Apr 5, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 29, 2021 RFCR
NON-FINAL ACTION WRITTEN
Mar 28, 2021 CNRT
ASSIGNED TO EXAMINER
Mar 22, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 8, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 2, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 26, 2020 REPR